HELEN HESLOP to Genetic Markers
This is a "connection" page, showing publications HELEN HESLOP has written about Genetic Markers.
Connection Strength
0.714
-
Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation. Hum Gene Ther. 1996 Mar 20; 7(5):655-67.
Score: 0.105
-
Use of gene marking in bone marrow transplantation. Cancer Detect Prev. 1996; 20(2):108-13.
Score: 0.104
-
Gene-marking and haemopoietic stem-cell transplantation. Blood Rev. 1995 Dec; 9(4):220-5.
Score: 0.103
-
Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3.
Score: 0.042
-
Gene-marking studies of hematopoietic cells. Int J Hematol. 2001 Jan; 73(1):14-22.
Score: 0.037
-
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998 Sep 01; 92(5):1549-55.
Score: 0.031
-
Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 1998 May 20; 9(8):1237-50.
Score: 0.031
-
Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol. 1998; 9 Suppl 5:S129-32.
Score: 0.030
-
Human gene marker/therapy clinical protocols. Hum Gene Ther. 1997 Dec 10; 8(18):2301-38.
Score: 0.030
-
Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Dec 01; 7(18):2287-313.
Score: 0.028
-
Transfer of marker genes into hemopoietic progenitor cells. Cytokines Mol Ther. 1996 Sep; 2(3):193-200.
Score: 0.027
-
Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Aug 20; 7(13):1621-47.
Score: 0.027
-
Gene transfer for the therapy of hematologic malignancy. Curr Opin Hematol. 1995 Nov; 2(6):417-22.
Score: 0.026
-
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995 Jan 07; 345(8941):9-13.
Score: 0.024
-
Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. Hum Gene Ther. 1994 Apr; 5(4):481-99.
Score: 0.023
-
Gene marking after bone marrow transplantation. Eur J Cancer. 1994; 30A(8):1171-6.
Score: 0.023
-
EBV specific CTL: a model for immune therapy. Vox Sang. 1998; 74 Suppl 2:497-8.
Score: 0.007
-
A yeast artificial chromosome (YAC) contig encompassing the critical region of the X-linked lymphoproliferative disease (XLP) locus. Genomics. 1997 Jan 01; 39(1):55-65.
Score: 0.007
-
Gene transfer and bone marrow transplantation. Cold Spring Harb Symp Quant Biol. 1994; 59:691-7.
Score: 0.006
-
Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet. 1993 Nov 06; 342(8880):1134-7.
Score: 0.006